TP53 and breast cancer: Considering the high risk of pulmonary metastasis in p53‐mutant breast cancers driven by C‐MYC,[29] we collected lung tissues from MDA‐MB‐231‐bearing mice on day 21 for H&E staining according to our previous work.[30] Compared to the shLuc control, PDCD11 silencing remarkably reduced the number of pulmonary metastatic nodules originating from the breast tumors (p < 0.001) (Figure 6F,G).